Dao Tun GmbH Switzerland

Dao Tun is a consulting company, founded in 2019, specialised in cross-border collaboration between Europe and China, primarily in the healthcare and life science industry.
Dao Tun is based in the Basel region, one of the world's leading clusters for Pharma and Life Sciences and also part of the trinational Biovalley region (Switzerland, Germany, France).
Dao Tun team provides customised strategy and execution plan via in-depth interview and targeted research; quickly gains insights into the association and matching between potential partners to make accurate and effective connections; simplifies the processes, reduces the cost of communication, and establishes the trust with full care.
Dao Tun is a bridge builder who excels at understanding and interpreting their interests and needs, and aligning perspectives of different stakeholders and across cultures for win-win-win situation.

Dr. Tianke Wang
Dr. Tianke Wang
CEO 
Functionality

DHVC United States

Life Science and Healthcare Venture Capital Investor
Website:
www.dh.vc
Company Size (Fulltime employees)
Year of foundation
2013
Partnering Objectives
Please specify your partnering goal
Investment
Headquartner in China
Medtech Development Stage
Ali Farahanchi
Managing Director 
Functionality

Elasmogen Ltd United Kingdom

Elasmogen, a next generation biologics company, develops soloMERs which are high affinity binding, single-domains; they are small (9% of an antibody), highly stable proteins and crucially are outside the complex/competitive antibody patent landscape. soloMERs are pre-disposed to generating potent neutralisers by binding to novel or cryptic epitopes. Their small size makes them ideal for both site-specific delivery and penetration of solid tumours. Our lead product, ADCP165, is an anti-ROR1 soloMER drug conjugate being co-developed with Almac Discovery. This program is tracking for entry into the clinic 2022/3 with follow on products in the pipeline. In addition our lead anti-auto-immune inflammatory domain, ELN/22, a tetravalent, bi-paratopic anti-TNF product is being developed for oral delivery for the treatment of IBD.
We are currently looking for partners for our existing assets and also companies who would like to access our powerful, patent protected soloMER platform to develop new products.
Company Size (Fulltime employees)
Year of foundation
2016
Please specify your partnering goal
Licensing of existing assets and co-development of new therapeutic development
Headquartner in China
Dr. Caroline Barelle
CEO 

Focus-X Therapuetics United States

Focus-X is a preclinical stage biotech company committed to the Discovery and development,, of personalized precision medicine fulfilling the unmet needs in cancer diagnosis and treatment. We are to release the true potential of radioligand therapy by leveraging our world class peptide drug discovery platform and joining force with top radiopharmaceutical partners.
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
Connection to investors and partners
Headquartner in China
Biotech/Pharma Asset Stage
Fa Liu
CEO 
Functionality

GCV Life India

Life science-focused Innovation licensing organizations looking to commercialize global innovations for the Indian and South Asian markets through a unique partnership-led model.
Dr. Chirag Jain
Analyst 
Functionality

GIG China

GIG, one of the leading healthcare investment institute, was founded in Shenzhen in 2001. AUM is RMB ¥20b. It has invested in 80+ healthcare companies. 22 went IPO. GIG has 90+ staff in team with operating offices in Shenzhen, Shanghai, Beijing, Nanjing and Hongkong.

Website:
www.szgig.com
Company Size (Fulltime employees)
Please specify your partnering goal
potential investing targets and collaborations
Headquartner in China
Medtech Development Stage
Denise Chen
Partner 
Functionality

HEC Pharm China

HEC Pharm is the pharmaceutical subsidiaries of HEC Group. There has been a public company listed in Hong Kong in HEC Pharm, and another company will be listed in Shanghai next year.

HEC Pharm focuses on the development and commercialization of pharmaceuticals for the therapeutics of anti-infectious diseases, metabolism disorders and oncology. We are hunting for the opportunities of co-development and in-license of the candidates with the potential therapeutics in previous fields.
Website:
www.hec.cn
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
out-license, in-license and co-development opportunities hunting
Headquartner in China
Lisha Chen
Senior Business Development Manager 
Functionality

Hengenix United States

Innovative biologics for cancer and other patients' unmet needs
Website:
Hengenix.com
Company Size (Fulltime employees)
Year of foundation
2010
Partnering Objectives
Please specify your partnering goal
co-dev
Headquartner in China
Wenfeng Xu
VP Research 

Huahai Investment Co., Ltd China

Huahai Investment Co, Ltd is a young, China-based firm backed by the Huahai Pharmaceuticals Group, a listed company in the Shanghai Stock Exchange. Our twin missions are to make investment as well as partnership deals in the healthcare sector.
Company Size (Fulltime employees)
Please specify your partnering goal
We are interested in investment and licensing deals with companies developing therapeutics in a wide variety of areas, including oncology, CNS diseases, ophthalmology, and infectious diseases.
Headquartner in China
Mr. Hanson Lo
Director, BD 
Functionality

INOVOTION France

CRO Preclinical
In vivo efficacy evaluation in oncology
Company Size (Fulltime employees)
Year of foundation
2015
Please specify your partnering goal
New customers and partners
Headquartner in China
Mr. Philippe Fornies
Head of Business Development 
Functionality